Keros Therapeutics (NASDAQ: KROS)
$53.60
(-4.7%)
-$2.64
Price as of April 25, 2024, 12:38 p.m. ET
Keros Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Keros Therapeutics Company Info
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
News & Analysis
Featured Article
Why Shares of Keros Therapeutics Jumped This Week
The company appointed a new director and an analyst reiterated his position on the stock.
Jim Halley | Apr 21, 2023
Featured Article
Why Shares of Keros Therapeutics Rose 10.2% This Week
A sympathetic reaction to a competitor's drug helped push the clinical-stage pharmaceutical company's shares higher.
Jim Halley | Oct 14, 2022
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.